3 Reasons Aphria (TSX:APHA) Stock Is Looking Better Than Ever

With its larger competitors beginning to stall out, Aphria Inc (TSX:APHA)(NYSE:APHA) is looking better than ever

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

Aphria Inc (TSX:APHA)(NYSE:APHA) has long been one of the more controversial marijuana stocks. Between short attacks, shareholder lawsuits, and a hostile takeover bid, the company has been involved in more drama than any of the other major weed producers. As a result of the bad press, Aphria was once among the most hated weed companies.

Now, however, with Canopy Growth Corp (TSX:WEED)(NYSE:CGC) losing money and other producers stalling out, it’s beginning to look like one of the best in its class. The following are just three reasons why Aphria stock is looking better than ever.

The fastest-growing weed producer

The most obvious thing that will stand out in Aphria’s third quarter earnings report is the incredible growth. At 617% year-over-year, it exceeds any other weed producer and puts the company within striking distance of Canopy’s sales figures. While Aphria’s recreational sales fell 35%, that was more than made up for by medical and revenue generated by new acquisitions: CC Pharma and ABP. Now, Aphria is just a smidgen smaller than Aurora–and a whole lot cheaper.

Last year’s drama completely resolved

Aphria’s stock suffered last year due to the highly publicized controversies it had been embroiled in. Now, it looks like it’s smooth sailing ahead. As previously mentioned, Aphria’s latest report revealed that much of its revenue is coming from new acquisitions CC Pharma and ABP–completely undermining the claim that such acquisitions had been worthless.

Additionally, most of the high-profile investors who had been short APHA have closed out their positions, so the “short attack” threat is no longer a factor. Finally, while the class-action lawsuit against Aphria appears to be going ahead, the company’s relative success in recent quarters could result in a favourable outcome for the company.

Larger competitors running into problems

A final factor making Aphria look good right now is the competitive landscape in the cannabis space. Simply put, many of Aphria’s competitors aren’t doing so well, which makes Aphria look good by comparison.

Case in point: Canopy Growth. In its most recent quarter, that company posted a $323 million net loss and a $174 million operating loss. In its full year results, it posted a $670 million loss. This is a company that’s burning through cash at a frightening pace–so much so that the markets aren’t rewarding its revenue growth.

The problems with Canopy recently got so bad that the company’s biggest investor publicly stated they were “not pleased” with their results–and may have instigated the ouster of CEO Bruce Linton.

In an industry in which disappointing results are becoming the norm, Aphria’s red-hot growth stands out. It should be noted that Aphria itself is running net losses, but they’re much smaller as a percentage of revenue than Canopy’s.

Additionally, Aphria has posted positive earnings in several quarters, thanks in no small part to its long-term investment portfolio, which may make Aphria look increasingly appealing as investors get hungry for earnings.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

More on Cannabis Stocks

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.
Cannabis Stocks

Canopy Growth: Is There Budding Potential in the Cannabis Market?

Canopy Growth stock hit 52-week lows recently on news of needing to re-file on its BIoSteel business, so what now?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

What’s Happening With Cannabis Stocks in May 2023?

Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is…

Read more »

Cannabis smoke
Cannabis Stocks

Are Cannabis Stocks a Good Buy in May 2023?

If you're going to buy cannabis stocks, these are pretty much the only two I would consider. Even so, you…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Aurora Cannabis: Time to Light Up Your Portfolio?

Here's my take on whether Aurora Cannabis (TSX:ACB) is worth adding to a growth portfolio right now, given its growth…

Read more »

Target. Stand out from the crowd
Tech Stocks

These Undervalued TSX Stocks Are a Bargain in May 2023

If you're willing to bet on a rebound, these are the three TSX stocks I would consider first as they…

Read more »

A cannabis plant grows.
Cannabis Stocks

Tilray Stock Is Scraping 52-Week Lows: Will it Bottom Out Soon?

Tilray (TSX:TLRY) stock remains down 53% in the last year, but when will this company hit the bottom and start…

Read more »

Medicinal research is conducted on cannabis.
Metals and Mining Stocks

2 Canadian Stocks That Are Simply Too Cheap to Avoid

These two Canadian stocks have sunk lower and lower, which is why now could be the right time for long-term…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

1 Marijuana Stock I’d Buy Over Aurora Cannabis

Explore a promising marijuana stock that outshines Aurora Cannabis. Unveil the investment opportunity to boost your cannabis portfolio.

Read more »